Veradermics — Third Quarter 2026 Earnings Summary

Veradermics reported positive topline results from its Phase 3 Study 304 and 12-month data from Phase 2/3 Study 302 for VDPHL01, an oral non-hormonal treatment for male pattern hair loss, demonstrating robust hair growth and a favorable safety profile. The company also announced positive Phase 2 results from open-label Study 207 in women with pattern hair loss and completed enrollment in the registration-directed Study 306, with topline data expected in the first half of 2027. For the third quarter ended September 30, 2026, Veradermics reported a net loss of $21.0 million and held $798.4 million in cash, cash equivalents, and marketable securities, which is projected to fund operations through 2030.